問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberON101CLCT02

2012-07-01 - 2020-06-30

Phase III

Terminated11

  • Trial Applicant

    ONENESS BIOTECH CO., LTD.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator 董光義 Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 陳錫根 Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 黃玄禮 Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Yu-Yao Huang Division of Endocrinology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 陳俊嘉 Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Hsin-Han Chen Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Naichen Cheng Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 陳建璋 Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator CHERNG-KANG PERNG Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Hsin-Han Chen Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 董光義 Division of Plastic Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    236 participants

  • Global

    236 participants